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Abstract
The use of nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer within UK clinical practice
was assessed. NPLD was most frequently (16 [25%] of 63 patients) administered ﬁrst-line (median, third-line;
in anthracycline-pretreated patients, median, fourth-line). Objective response occurred in 29% of patients
(anthracycline naive, 75%; pretreated, 15%). Toxicities tended to be grade 1 or 2. NPLD had clinical activity
in anthracycline-naive and pretreated patients, with low toxicity.
Background: This study aimed to investigate the use of nonpegylated liposomal doxorubicin (NPLD) in the
management of metastatic breast cancer (MBC) within routine UK clinical practice and to assess its efﬁcacy and
tolerability. Patients and Methods: All patients that received NPLD for MBC at 5 institutions were identiﬁed.
Clinicopathologic details, echocardiographic data, and toxicities were documented. Response to treatment, outcome,
cardiotoxicity, and safety were assessed. Results: 63 patients (median age at NPLD therapy, 53.5 years) who had
received NPLD were identiﬁed; 18 (29%) were anthracycline-naïve, and 42 (67%) were anthracycline-pretreated
(median cumulative dose of epirubicin, 450 mg/m2). In 3 cases, prior treatment history was not available. NPLD
was most frequently (16 [25%] of 63 patients) administered as ﬁrst-line chemotherapy (median, third-line; range, 1-9),
although it was given later in anthracycline-pretreated patients (median, fourth-line; range, 1-9). Overall, 14 (29%)
of 49 evaluable patients achieved an objective response, which increased to 10 (71%) of 14 when NPLD was given
ﬁrst-line (anthracycline-naïve, 8 [100%] of 8; anthracycline-pretreated, 2 [50%] of 4; adjuvant treatment unknown,
2). Median progression-free survival was 7 months (ﬁrst-line, 18 months, vs.  second-line, 6 months; P ¼ .0066), and
median overall survival was 10 months (ﬁrst-line, 18 months, vs.  second-line, 10 months; P ¼ .0971). Toxicities
tended to be grade 1 or 2. Three patients had cardiotoxicity (left ventricular ejection fraction < 50% or a fall of  10%
from baseline), which resolved during treatment. Conclusion: NPLD was used in both anthracycline-naïve patients
and those with prior exposure. There is evidence of clinical activity in those with prior exposure to anthracyclines, with
a low incidence of cardiotoxicity.ical Breast Cancer, Vol. 14, No. 2, 85-93 ª 2014 The Authors. Published by Elsevier Inc.
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Anthracycline-based regimens are some of the most active cyto-
toxic treatments for breast cancer.1 For patients requiring chemo-
therapy, they remain a key part of most adjuvant treatments and a
standard ﬁrst-line therapy in de novo metastatic disease.1,2 In both
early and advanced disease, such regimens have been found to
signiﬁcantly increase disease-free and overall survival compared with non-
anthracycline-containing regimens.3-5 The recent advent of third-
generation adjuvant chemotherapy regimens, in which anthracyclines are
sequenced or combined with taxanes, has raised questions about the
optimal management of those patients who relapse with human epidermal
growth factor receptor 2enegative (HER2, ERBB2) disease requiring
chemotherapy, as well as questions about the potential role for reexposure/
rechallenging with an anthracycline or taxane. To date, there have been no
prospective trials speciﬁcally looking at chemotherapeutic management
in anthracycline- or taxane-pretreated patients. Current therapeutic options
for patients treated adjuvantly with an anthracycline and taxane include
capecitabine, vinorelbine, and eribulin; however, few studies clearly stratify
and account for previous adjuvant anthracycline or taxane exposure.6
A recent systematic review has highlighted the potential for
rechallenging with anthracyclines and taxanes in the metastatic
setting, although the evidence is again somewhat limited.6
Consensus guidance from Europe and the United Kingdom
indicate that patients relapsing > 12 months after anthracycline-
based treatment may be re-treated with an anthracycline up to
cumulative doxorubicin and epirubicin dose levels of 450 to 550
and 800 to 1000 mg/m2, respectively.7,8 The use of a liposomal
anthracycline should be considered in patients who have reached or
are near the cumulative cardiotoxicity threshold or have other
cardiac risk factors.7-9
Liposomal anthracyclines, such as nonpegylated liposomal
doxorubicin (NPLD) (Myocet) have been found to have antitumor
efﬁcacy similar to that of doxorubicin when used as ﬁrst-line therapy
for metastatic breast cancer (MBC), but with a signiﬁcantly
improved cardiac proﬁle.10-12 A post hoc analysis of the trial data
has also suggested that NPLD might have potential efﬁcacy
advantages over doxorubicin, as well as reduced cardiotoxicity, when
used in patients treated with adjuvant anthracyclines.13 In this
analysis, 68 patients from 2 randomized controlled trials10,14
received NPLD 60 mg/m2 in combination with cyclophospha-
mide 600 mg/m2 or NPLD 75 mg/m2 as monotherapy, or the
equivalent doxorubicin regimen, as ﬁrst-line treatment.13 Patients
had received a median of 240 mg/m2 of doxorubicin as adjuvant
therapy. The primary efﬁcacy endpoint of overall response rate
was signiﬁcantly higher in NPLD patients at 31%, vs. 11% for
doxorubicin-treated patients (P ¼ .04). Median time to treatment
failure was also signiﬁcantly improved in NPLD patients in com-
parison with doxorubicin patients (4.2 vs. 2.1 months, respectively;
P ¼ .01), although median time to progression (4.5 vs. 3.4 months;
P ¼ .66) and median survival time (16 vs. 15 months; P ¼ .71)
were similar for the 2 treatments. Cardiac events (reduction in left
ventricular ejection fraction [LVEF]) occurred in signiﬁcantly fewer
NPLD than doxorubicin patients (22% vs. 39%, respectively;
P ¼ .001), and the median lifetime dose at onset of cardiotoxicity
also signiﬁcantly favored the liposomal preparation (780 mg/m2 vs.
580 mg/m2; P ¼ .001).13 Recent expert consensus groups haveClinical Breast Cancer April 2014indicated that the use of liposomal doxorubicin in patients previ-
ously exposed to anthracyclines is a reasonable treatment option.7,8
Given that the current data on the clinical use of NPLD are
scarce, this study was conducted to provide a multicenter,
retrospective review of the use of NPLD for the treatment of MBC,
to investigate where and how it is used in UK clinical practice, and
to assess the efﬁcacy and tolerability of NPLD.
Patients and Methods
Patient Population
Case notes were identiﬁed, and relevant data extracted, for
patients treated with NPLD for MBC between 1998 and 2011
at Charing Cross Hospital, London; Christie Hospital, Manchester;
Rivers Hospital, Sawbridgeworth; Ross Hall Hospital, Glasgow; and
Spire Bushey Hospital, Watford, United Kingdom. Patients were
excluded from analysis if it was not possible to conﬁrm NPLD
treatment from their notes.
Data Collection
All clinical and histopathologic data were anonymized.
Demographic information, details of adjuvant therapy and
surgery, metastatic therapy up to and including the use of NPLD,
echocardiograph (ECHO) results, adverse events, and
progression and survival data were recorded. Treatment details
included the dates that therapy was commenced and completed, the
response to therapy, and the dosage of any anthracyclines
administered.
Study Outcomes and Analysis
The primary outcomes of interest were the place of NPLD
in metastatic therapy relative to other treatments and how this
varied according to previous use of anthracyclines; the efﬁcacy of
NPLD treatment; and the safety proﬁle of NPLD. The place
of NPLD in therapy was deﬁned according to the line of chemo-
therapy. The line of systemic treatment, including endocrine
therapies, where NPLD was used was also captured as a secondary
measure. Efﬁcacy of NPLD was deﬁned according to the best
response to treatment (complete/partial response [CR/PR]; stable
disease [SD]; progressive disease [PD]), as determined by the
treating clinician, and according to survival (estimated, using
the Kaplan-Meier method, from metastatic diagnosis and the start
of NPLD therapy); patients were also split according to whether
they had received NPLD as ﬁrst-line chemotherapy for metastatic
disease or later in treatment. Patients were deﬁned as having
experienced NPLD cardiotoxicity (1) if they had a baseline LVEF
of > 50% and experienced a fall in LVEF to < 50% or a fall
of  10% from baseline during or in the 3 months after therapy or
(2) if they had a baseline LVEF of < 50% and they experienced
a fall of  10% from baseline during or in the 3 months after
therapy. Baseline LVEF was deﬁned as being derived from ECHO
scans taken within 3 months preceding the start of therapy. Patients
without a baseline ECHO or subsequent ECHO taken during
therapy or within 6 months after the end of therapy were excluded
from analysis. The incidence and severity (according to the
Common Terminology Criteria for Adverse Events [CTCAE]
version 4.0)15 of adverse events recorded during therapy with
Table 1 Baseline Characteristics and Adjuvant Treatment
Details
Variable Value
Gender
Female, n (%) 62 (98.4%)
Male, n (%) 1 (1.6%)
Median Age at Initial Diagnosis, years (range) 46.6 (30.0-75.0)
Median Age at Metastatic Disease, years (range) 51.3 (32.0-81.3)
Median Age at Treatment with NPLD, years (range) 53.5 (32.0-85.8)
Diagnosed with Metastatic Disease, n (%) 7 (11.1%)
Hormone Receptor Status, n (%)
ERþ/PRþ 23 (36.5%)
ERþ/PR 8 (12.7%)
ERþ/PR unknown 12 (19.0%)
ER/PRþ 2 (3.2%)
ER/PR 13 (20.6%)
ER unknown/PR unknown 5 (7.9%)
HER2 Status, n (%)
HER2þ 19 (30.2%)
HER2 30 (47.6%)
Unknown 14 (22.2%)
Sites of First Relapse, n (%)
Locoregional only 14 (22.2%)
Locoregional and distant 13 (20.6%)
Distant 36 (57.1%)
Sites of Distant Metastases, n (%)
Bone 25 (39.7%)
Brain 4 (6.3%)
Liver 17 (27.0%)
Lung 7 (11.1%)
Neck 1 (1.6%)
Soft tissue/skin 8 (12.7%)
Stomach 1 (1.6%)
No. of Sites of First Relapse
1 41 (65.1%)
2 14 (22.2%)
3 8 (12.7%)
Treated for Early Disease 56 (88.9%)
Adjuvant chemotherapy, n (%)
Anthracycline 16 (28.6%)
Taxane 5 (8.9%)
Anthracycline and taxane 8 (14.3%)
Other (CMF) 6 (10.7%)
None 18 (32.1%)
Unknown 3 (5.4%)
Adjuvant endocrine therapy, n (%)
ERþ, yes 29 (67.4%)
ERþ, no 12 (27.9%)
ERþ, unknown 2 (4.7%)
ER, yes 1 (6.7%)
ER, no 10 (66.7%)
ER, unknown 4 (26.7%)
Table 1 Continued
Variable Value
Unknown, yes 0 (0.0%)
Unknown, no 2 (40.0%)
Unknown, unknown 3 (60.0%)
Adjuvant trastuzumab, n (%)
HER2þ, yes 9 (47.4%)
HER2þ, no 6 (31.6%)
HER2þ, unknown 4 (21.1%)
HER2, yes 0 (0.0%)
HER2, no 30 (100.0%)
Unknown, yes 0 (0.0%)
Unknown, no 11 (78.6%)
Unknown, unknown 3 (21.4%)
Adjuvant radiotherapy, n (%)
Yes 39 (69.6%)
No 10 (17.9%)
Unknown 7 (12.5%)
Surgery, n (%)
Yes 49 (87.5%)
No 4 (7.1%)
Unknown 3 (5.4%)
Abbreviations: CMF ¼ cyclophosphamide/methotrexate/5-ﬂuorouracil; ER ¼ estrogen receptor;
FILM ¼ 5-ﬂuorouracil/ifosfamide/leucovorin/mitomycin; HER2 ¼ human epidermal growth
factor receptor 2 (ERBB2); LN ¼ lymph node; NPLD ¼ nonpegylated liposomal doxorubicin;
PR ¼ progesterone receptor.
Carlo Palmieri et alNPLD were described as a proportion of the patients for whom
such data were available.
Results
Baseline Characteristics
A total of 63 patients with MBC who had received NPLD were
identiﬁed; the median age at treatment with NPLD was 53.5 years,
and 7 patients (11%) were diagnosed with metastatic disease. The
clinicopathologic features are summarized in Table 1.
Adjuvant Anthracyclines Exposure Before NPLD
Among the 56 patients diagnosed with early breast cancer (EBC),
35 (63%) had received adjuvant chemotherapy; 24 (69%)
of 35 were exposed to an anthracycline, with the remaining
11 (31%) receiving a non-anthracycline-containing regimen
(see Table 1). Altogether, 17 (30%) of 56 diagnosed with EBC
received no adjuvant chemotherapy, with treatment history
unavailable in 3 cases.
In those exposed to an adjuvant anthracycline, epirubicin was the
most commonly used in 18 (75%) of the 24 patients (median
cumulative dose, 450 mg/m2; range, 240-600 mg/m2). Of the
remainder, 4 (17%) received NPLD (median cumulative dose,
300 mg/m2), 1 (4%) received doxorubicin (cumulative dose,
240 mg/m2), and 1 (4%) receivedMMM (mitomycin/methotrexate/
mitoxantrone; cumulative dose, 56 mg/m2). Trastuzumab was
administered to 9 patients (16%) and radiotherapy to 39 patients
(70%) with EBC, and 49 (88%) of these patients had surgery.
For patients with EBC, the median time to relapse from diagnosis wasClinical Breast Cancer April 2014 - 87
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88 -44.8 months (range, 0.6-178.5 months); from completion of
adjuvant anthracycline and/or taxane therapy, the median time was
16.3 months (range, 0.0-79.3 months).
Use of Anthracyclines for Metastatic Disease Before NPLD
Twenty-one (33%) of the 63 patients received anthracycline
therapy for MBC before NPLD, most frequently (14 patients; 67%)
as ﬁrst-line chemotherapy. Of these 21 patients, 17 (81%) received
epirubicin (median cumulative dose, 435 mg/m2; range, 180-660
mg/m2) and 4 (19%) received doxorubicin (median cumulative
dose, 300 mg/m2; range, 300-450 mg/m2). Three (14%) of the
21 patients receiving epirubicin for MBC had also received adjuvant
anthracyclines.
Total Anthracycline Exposure Before NPLD Treatment
In total, 42 (67%) of the 63 patients were anthracycline
pretreated before receiving NPLD for MBC; 21 (50%) of the
42 had received anthracyclines in the adjuvant setting only,
18 (43%) for metastatic disease alone, and 3 (7%) for both early and
metastatic disease. The median cumulative dose of epirubicin
(adjuvant and metastatic) was 450 mg/m2 (range, 240-975 mg/m2).
NPLD Use in the Metastatic Setting
Whole Cohort (Anthracycline Naïve and Pretreated). NPLD was
most frequently, in 16 (25%) of the 63 patients, administered as ﬁrst-line
chemotherapy for MBC (median, third-line; range, 1-9) (Fig. 1).
The place of NPLD in all systemic therapy is shown in Figure 1.
Anthracycline-Naïve Patients. Within the cohort, 18 (29%) of the
63 were anthracycline naïve; the median line of use of NPLD
in these cases was second-line (range, 1-4). However, 9 (50%) of
these 18 patients received NPLD as ﬁrst-line chemotherapy forFigure 1 Line of Therapy in Which Nonpegylated Liposomal Doxoru
(Anthracycline Naïve and Pretreated). A, Chemotherapies
Median Line of Chemotherapy ¼ Third-Line.
Median Line of Systemic Therapy ¼ Fifth-Line.
Clinical Breast Cancer April 2014MBC (Fig. 2). Of the 36 patients who did not receive adjuvant
anthracyclines, 14 (39%) did not receive ﬁrst-line treatment with
NPLD or other anthracycline for MBC; in these cases, ﬁrst-line
regimens included capecitabine, paclitaxel, bevacizumab/paclitaxel,
vinorelbine, gemcitabine/carboplatin, and gemcitabine/paclitaxel.
Anthracycline-Pretreated Patients. In the 42 patients previously
exposed to anthracyclines (21 in the adjuvant setting only; 18 in
the metastatic setting only; 3 in both settings), NPLD was given
most frequently (in 10 patients; 42%) as third-line chemotherapy
(median, fourth-line; range, 1-9) (see Fig. 2). The median time from
completion of previous anthracycline therapy to administration of
NPLD was 35 months (range, 1-215 months). Taking into account
the setting of prior anthracyclines exposure, those exposed to
anthracyclines within the adjuvant setting were exposed to NPLD
earlier in their metastatic treatment (as line of chemotherapy)
compared with those in whom anthracyclines were used in the
metastatic setting (median line of chemotherapy treatment, third
vs. sixth, respectively).
Response to Treatment
Whole Cohort. Forty-nine (78%) of the 63 patients were evaluable
for response (34 anthracycline-pretreated patients; 12 anthracycline-
naïve patients; 3 with unknown adjuvant treatment history). NPLD
resulted in an objective response (OR) (where OR ¼ CR þ PR)
in 14 (29%) of the 49 evaluable patients. A further 17 patients
(35%) had SD, meaning that 31 (63%) of the 49 patients achieved
clinical beneﬁt (CR, PR, or SD) from NPLD therapy. Eight (75%)
of the 12 anthracycline-naïve patients had an OR, compared
with 5 of the 34 anthracycline-pretreated patients (15%). All
12 anthracycline-naïve patients (100%) derived clinical beneﬁt from
NPLD therapy, compared with 17 (50%) of the 34 pretreatedbicin (NPLD) was Used for Metastatic Disease for all Patients
Only. B, Any Systemic Therapy
Figure 2 Line of Therapy in Which Nonpegylated Liposomal Doxorubicin (NPLD) was Used for Metastatic Disease According to
Previous Anthracycline Use. A, Chemotherapies Only. B, Any Systemic Therapy
Median Line of Chemotherapy: Naïve ¼ Second-Line; Pretreated ¼ Fourth-Line.
Median Line of Systemic Therapy: Naïve ¼ Second-Line; Pretreated ¼ Eighth-Line.
Data Available for 60 Patients; 3 Patients With Unknown Adjuvant Chemotherapy Treatment History Were Excluded.
Carlo Palmieri et alpatients. In those cases that were rechallenged with NPLD, the
OR rate (ORR) was highest if NPLD was given earlier rather than
later in therapy (Fig. 3).
By Line of Treatment. First-line Treatment
In the 14 patients receiving NPLD as ﬁrst-line chemotherapy
treatment (4 anthracycline-pretreated patients; 8 anthracycline-
naïve patients; 2 with unknown adjuvant treatment history),Figure 3 Best Response to Nonpegylated Liposomal Doxorubicin Th
Anthracycline-Pretreated Patients
Response Data Were Unavailable for 14 Patients, Including 8 Anthracycline-Experienced Patients.
Abbreviations: CR ¼ complete response; PR ¼ partial response.10 (71%) had an OR (see Fig. 3). Based on prior anthracycline
exposure (naïve vs. rechallenged), this was 8 (100%) of 8
and 2 (50%) of 4, respectively. The 2 remaining anthracycline-
pretreated patients progressed.
Second and Subsequent Lines of Treatment. When NPLD was
given as a second or subsequent line of chemotherapy, 4 of 35
patients (30 anthracycline-pretreated patients; 4 anthracycline-naïveerapy. A, All Patients (Anthracycline Naïve and Pretreated). B,
Clinical Breast Cancer April 2014 - 89
Figure 4 Progression-Free Survival (PFS) From the Start of Nonpegylated Liposomal Doxorubicin Therapy When Given as First-line
Chemotherapy or Later in Treatment (Second-line and Beyond)
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90 -patients; 1 with unknown adjuvant treatment history) had an OR
(11%) and 16 derived clinical beneﬁt (46%) (see Fig. 3). Based on
prior anthracycline exposure (naïve vs. rechallenged), this was
0 (0%) of 4 patients and 3 (10%) of 30 patients, respectively. Of
the 4 anthracycline-naïve patients who received NPLD as second-
line or later chemotherapy, all had SD. For anthracycline-
pretreated patients receiving NPLD second- or third-line, the
ORR was 23% and the clinical beneﬁt rate was 54%. No
anthracycline-pretreated patients achieved an OR when NPLD wasFigure 5 Overall Survival (OS) From the Start of Nonpegylated Liposo
or Later in Treatment (Second-line and Beyond)
Clinical Breast Cancer April 2014given fourth-line or beyond, although around half of patients (44%-
50%) had SD.
Overall, in the 34 patients who were rechallenged with NPLD
for whom OR was documented, 5 (15%) had an OR and 17 (50%)
achieved clinical beneﬁt.
Progression-Free and Overall Survival
For the whole cohort, the median progression-free survival
(PFS) from the start of NPLD therapy was 7 months (95% CI,mal Doxorubicin Therapy When Given as First-line Chemotherapy
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Carlo Palmieri et al4.8-9.2 months). For patients who received NPLD as ﬁrst-line
chemotherapy, the median PFS was 18 months, whereas for those
who received NPLD later in treatment (second-line and beyond), the
median PFS was 6 months (P ¼ .0066) (Fig. 4). Anthracycline-naïve
patients had a greater median PFS than anthracycline-pretreated
patients (14 months [95% CI, 8.3-19.7 months] vs. 4 months [95%
CI, 2.2-5.8 months]; hazard ratio [HR], 0.37; P ¼ .0006).
Median overall survival (OS) from metastatic diagnosis was
45 months (95% CI, 29.3-60.7 months), and median OS was
10 months (95% CI, 8.0-12.0 months) from the start of NPLD
therapy. For patients receiving NPLD as ﬁrst-line chemotherapy,
median OS (from the start of NPLD therapy) was 18 months,
compared with 10 months where it was used as second-line and
beyond (P ¼ .0971) (Fig. 5). Anthracycline-naïve patients had
a median OS of 14 months (95% CI, 7.6-20.4 months) from the
start of NPLD therapy, which was signiﬁcantly longer than for
anthracycline-pretreated patients (10 months [95% CI, 8.9-11.1
months]; HR, 0.51; P ¼ .0423).
Cardiotoxicity
All patients had normal cardiac function before commencing
NPLD. During NPLD therapy, there were 3 documented cases
of cardiotoxicity according to the deﬁned LVEF criteria. This
resolved in all 3 patients (LVEF returning to > 50% and to within
10% of baseline). In 1 case, in which the patient was anthracycline
naïve, the NPLD (third-line chemotherapy) was not restarted,
owing to disease progression (cumulative dose, 120 mg/m2 NPLD).
In the other 2 cases, 1 patient was anthracycline naive, had an LVEF
of 48% (baseline, 62%), and experienced shortness of breath during
treatment, whereas the other had received adjuvant epirubicin
(600 mg/m2), experiencing a fall in LVEF > 10% from baseline
during NPLD treatment (but the LVEF remained above 50%). The
former went on to receive 400 mg/m2 NPLD as ﬁrst-line therapy
for metastatic disease, whereas the latter received 360 mg/m2
of NPLD as third-line chemotherapy.
Toxicity
The majority of toxicities were grade 1 to 2 in severity, with the
exception of neutropenia and alopecia (Table 2). No incidences
of cardiomyopathy or heart failure were reported that were
considered to be associated with NPLD. One patient discontinued
treatment, owing to chest pains and headache, although this was not
deemed to be cardiac-related.
Discussion
Adjuvant anthracycline/taxane regimens are now routinely used
for the management of high-risk EBC and signiﬁcantly reduce
the annual mortality rate from the disease by 13%.16 However,
even with the use of such regimens, approximately 5% per year
relapse.17,18 The optimal therapy for patients who develop advanced
disease after sequential anthracycline/taxane therapy is unclear.
A clinically relevant and pertinent question is whether there is a role
for further anthracycline or taxane treatment after relapse after such
adjuvant treatment. Various studies provide evidence for the possible
efﬁcacy of rechallenging with these agents, although no formal phase
III randomized data exist.6 In the case of anthracyclines, liposomal
formulations, such as NPLD, have been suggested for use in patientsClinical Breast Cancer April 2014 - 91
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92 -close to the cumulative dose threshold for anthracycline cardiotox-
icity, on the basis of their reduced cardiotoxicity and equivalent
efﬁcacy to conventional doxorubicin.9,10,14 Data from an
unplanned subgroup analysis provide the only current data on the
possible efﬁcacy of NPLD in patients previously exposed to an
anthracycline.13 The data presented in this article are the ﬁrst to
assess the use of NPLD in a routine clinical practice, and they
provide insight into how NPLD has been used and into the treat-
ment outcomes.
The current data indicate that NPLD is used in a broad fashion
in MBC, with its use ranging from ﬁrst-line to ninth-line
chemotherapy (or up to fourteenth-line, when endocrine therapies
are included). Analysis of treatment history also found that NPLD
was used in both anthracycline-naïve patients and anthracycline-
pretreated patients (exposed either adjuvantly or in the metastatic
setting). Use of NPLD as a ﬁrst-line chemotherapy for MBC
was most common in patients who were anthracycline-naïve,
whereas patients who had received prior anthracyclines tended
to receive NPLD later in the course of metastatic therapy. However,
interestingly, among patients who ﬁrst received an anthracycline
in the metastatic setting (NPLD or otherwise), only 65% were
treated with an anthracycline-containing regimen ﬁrst-line.
Although the reasons for this were not documented, they are
likely to include the subtype of breast cancer, preference for oral
therapy, and tolerability/toxicity considerations; however, all these
patients went on to receive at least 1 line of anthracycline therapy.
This study’s ORR of 71% for NPLD when administered as
ﬁrst-line chemotherapy was considerably higher than the response
rates of between 26% and 46% reported in the pivotal clinical trials
of ﬁrst-line use of NPLD in MBC.10,11,14 Similarly, this study’s
median PFS of 18 months for ﬁrst-line treatment was higher than
the range of 2.9 to 7.7 months observed in the 3 main trials.10,11,14
Survival, however, was similar, at 18 months in this study vs. 16 to
19 months in the trials.10,11,14 The impressive response rate seen
in this study could be reﬂective of what happens in clinical practice,
in that patients were preferentially selected for NPLD therapy
if it was thought that they would respond well to anthracycline-
based treatment. Partial support for this conjecture comes from
the fact that a greater proportion of the patients had received
adjuvant anthracycline therapy (29%) than in the pivotal studies
(0%-17%),10,11,14 and that the median time from completion of
previous anthracycline therapy to administration of NPLD was
35 months in this study, indicating a signiﬁcant disease-free period,
suggestive of anthracycline sensitivity. An interval of at least
12 months between completion of previous anthracycline therapy
and rechallenging has been suggested by Coleman et al7 and Beslija
et al,8 which is in line with the present results.
It is also important to note that in this study less than a quarter
of patients received NPLD ﬁrst-line (median, third-line). Patients
receiving NPLD second- or third-line achieved anORR of 21%, with
more than 50% of patients maintaining SD when the drug was given
as sixth- or seventh-line therapy. Although earlier use of NPLD in
metastatic therapy, as expected, resulted in a better response and
longer PFS and OS, the results highlight that some patients might
gain continuing beneﬁt from anthracycline therapy, even late in their
disease, and that consideration should always be given to
reintroducing this therapy in suitable patients. The results in theClinical Breast Cancer April 2014rechallenge setting strengthen this argument. The ORR for patients
rechallenged with NPLD was 15%, which increased to 50% when
considering ﬁrst-line rechallenge only. Similar to the situation in the
total population, the ﬁrst-line results for rechallenge were higher than
those published in the post hoc analysis by Batist et al13 (which re-
ported anORR of 31%), again suggesting that outcomes with NPLD
in clinical practice might be better, with appropriate patient selection,
than those reported in the clinical trials.
NPLD seemed to have an acceptable toxicity and tolerability
proﬁle, with the majority of adverse events being mild to moderate
and with only 1 patient having to discontinue NPLD, owing
to chest pains and headache (which were not considered cardiac-
related). Given that the majority of patients (67%) were anthracy-
cline experienced, the lack of any signiﬁcant cardiac abnormalities
while patients were receiving NPLD was reassuring, although longer
cardiac follow-up would have been desirable. Neutropenia, as
expected, was found to be the most signiﬁcant adverse event,
although the results compared favorably with the clinical studies of
NPLD,10,11,14 with no patients reported as requiring a dose
reduction or a cessation of treatment as a result of neutropenic fever.
Limitations of this study include its retrospective nature, the
small patient population, and the lack of a comparator group.
Moreover, given the long period during which data were collected,
some patients’ treatment choices were not necessarily representative
of current practice; for example, trastuzumab was used in only half
of HER2þ patients, whereas today one would expect this ﬁgure to
be approaching 100%. These limitations aside, the data indicate the
efﬁcacy of NPLD in anthracycline-naïve patients, supporting the
importance of this key class of chemotherapy in breast cancer. The
data also indicate the efﬁcacy of NPLD as rechallenge treatment
in patients previously exposed to anthracycline, particularly when it
is used as early treatment in metastatic disease.Conclusion
This study found that within the context of routine clinical
practice, NPLD is being used in a broad fashion. Beneﬁts were seen
with NPLD when used after prior exposure to anthracyclines, with
a low incidence of cardiotoxicity. For patients relapsing after
adjuvant anthracycline and taxane treatment, the results suggest that
rechallenging with a liposomal agent is a therapeutic option that can
be considered. The beneﬁts of rechallenging with anthracyclines
or taxanes need to be formally tested in a randomized study.
Clinical Practice Points
 The increasing use of anthracyclines in sequence or combination
with taxanes as adjuvant therapy for breast cancer has raised
issues as to the optimal management of those patients who
relapse and require further chemotherapy. Expert groups have
suggested that rechallenging with liposomal formulations
of doxorubicin, which are known to be as efﬁcacious as
conventional doxorubicin while being less cardiotoxic, might be
an option for some patients. However, there are currently limited
data available on which to assess the efﬁcacy and tolerability of
rechallenging with a liposomal formulation.
 This study assessed how NPLD is currently being used in routine
clinical practice and to what effect. It found that NPLD has been
Carlo Palmieri et alused in a wide variety of patients, both anthracycline naïve and
pretreated, with good outcome and a low incidence of toxicity.
The beneﬁts of NPLD were greatest when it was used as ﬁrst-line
therapy or early in the course of treatment. There also seems to
be a role for NPLD as rechallenge therapy, with the present
results indicating that appropriate patient selection may
contribute to increased response rates compared with those
reported in the pivotal NPLD trials.
 With many patients now relapsing with secondary disease after
adjuvant anthracycline and taxane therapy, this study’s results
suggest that rechallenge with a liposomal agent should be
considered a potentially effective option for some patients.
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